Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multicenter, Randomized, Controlled, Open-Label, Perioperative Study of AG-120 and AG-881 in Subjects With Recurrent, Non-Enhancing, IDH1 Mutant, Low Grade Glioma

Next Previous
X
Search
Trial Profile

A Phase 1, Multicenter, Randomized, Controlled, Open-Label, Perioperative Study of AG-120 and AG-881 in Subjects With Recurrent, Non-Enhancing, IDH1 Mutant, Low Grade Glioma

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ivosidenib (Primary) ; Vorasidenib (Primary)
  • Indications Astrocytoma; Glioma; Oligodendroglioma
  • Focus Biomarker; Pharmacodynamics
  • Acronyms Window
  • Sponsors Agios Pharmaceuticals

    • Most Recent Events

    • 22 Feb 2024 Planned End Date changed from 1 May 2024 to 1 May 2025.
    • 08 Jun 2021 Results assessing biological impact of D-2-hydroxyglutarate suppression on tumors and tumor immune microenvironment presented at the 57th Annual Meeting of the American Society of Clinical Oncology
    • 07 Jun 2021 According to a Servier media release, Ingo Mellinghoff, M.D., Memorial Sloan Kettering Cancer Center, is an investigator for the study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top